Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0140
EDITORIAL
|
KRAS-targeting agents and beyond for colorectal cancer treatment
|
Christos S. Katsios, M.D.
|
Affiliation: Christos Katsios, Associate Professor of Surgery , Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.
Tel: +2651099696
E-mail: chkatsios@gmail.com |
ABSTRACT
Randomized controlled trials have shown an activity of monoclonal antibodies cetuximab and panitumumab in patients with wild-type metastatic colorectal cancer. These tumor-guided drugs demonstrate aldo an efficacy in patients with wild-type BRAF status permitting a further selection of patients and potential increased effectiveness. Here I discuss these latest advances as well the limitations of these agents and the perspectives for their clinical utility in the adjuvant setting. Moreover, it is discussed the novel direction of networks-based future agents.
(Citation: Gastric & Breast Cancer 2010; 9(4): 163-169)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
